Laboratory and clinical studies on SY5555 for urinary tract infections and prostatitis

A new oral penem antibiotic, SY5555, was administered in the treatment of urinary tract infection and prostatitis. The drug was given at doses of 300∼600 mg a day for 3∼14 days. The clinical efficacy was evaluated by the Japanese UTI Committee criteria in 44 of 58 patients treated. The efficacy was 100% in 24 cases of acute uncomplicated cystitis, and 60%(9 of 15) in chronic complicated UTI. Among 3 cases of acute bacterial prostatitis caused by Escherichia coli, bacteriological eradication was achieved in only one case. In the safety profile, adverse events were noted in 7 cases (12.5%) including mainly digestive disorders such as diarrhea or loose stool. No abnormal values were detected except for slight elevation of γ-GTP in one case.